The prognosis is influenced by several factors, including tumour size, degree of invasion and metastasis, histologic type, and nuclear grade. Staging is the most important factor in the outcome of renal cell cancer. The following numbers are based on patients first diagnosed in 2001 and 2002 by the National Cancer Data Base: Stage Description 5 Year Survival Rate I Confined to the kidney 81% II Extend through the renal capsule, confined to Gerota's Fascia 74% III Include the renal vein, or the hilar lymph nodes 53% IV Includes tumors that are invasive to adjacent organs (except the adrenal glands), or distant metastases 8% A Korean study estimated a disease-specific overall 5-year survival rate of 85%. Taken as a whole, if the disease is limited to the kidney, only 20–30% develop metastatic disease after nephrectomy. More specific subsets show a five-year survival rate of around 90–95% for tumors less than 4 cm. For larger tumors confined to the kidney without venous invasion, survival is still relatively good at 80–85%. For tumors that extend through the renal capsule and out of the local fascial investments, the survivability reduces to near 60%. Factors as general health and fitness or the severity of their symptoms impact the survival rates. For instance, younger people (among 20–40 years old) have a better outcome despite having more symptoms at presentation, possibly due to lower rates spread of cancer to the lymph nodes (stage III). Histological grade is related to the aggressiveness of the cancer, and it is classified in 4 grades, with 1 having the best prognosis (5 year survival over 89%), and 4 with the worst prognosis (46% of 5 year survival). Some people have the renal cell cancer detected before they have symptoms (incidentally) because of the CT scan (Computed Tomography Imaging) or ultrasound. Incidentally diagnosed renal cell cancer (no symptoms) differs in outlook from those diagnosed after presenting symptoms of<unk>  or metastasis. The 5 year survival rate was higher for incidental than for symptomatic tumours: 85.3% versus 62.5%. Incidental lesions were significantly lower stage than those that cause symptoms, since 62.1% patients with incidental<unk>  were observed with Stage I lesions, against 23% were found with symptomatic<unk> . If it has metastasized to the lymph nodes, the 5-year survival is around 5% to 15%. For metastatic<unk> , factors which may present a poor prognosis include a low Karnofsky performance-status score (a standard way of measuring functional impairment in patients with cancer), a low haemoglobin level, a high level of serum lactate dehydrogenase, and a high corrected level of serum calcium. For non-metastatic cases, the Leibovich scoring algorithm may be used to predict post-operative disease progression.<unk>  is one of the cancers most strongly associated with paraneoplastic syndromes, most often due to ectopic hormone production by the tumour. The treatment for these complications of<unk>  is generally limited beyond treating the underlying cancer.
Renal cell carcinoma
Renal medullary carcinoma
Renal oncocytoma
Papillary renal cell carcinoma
Renal anaplastic sarcoma
Renal medullary fibroma
Clear cell renal cell carcinoma
Clear cell papillary renal cell carcinoma